603 related articles for article (PubMed ID: 14743504)
41. Expression of extracellular matrix proteins in ovarian serous tumors.
Salani R; Neuberger I; Kurman RJ; Bristow RE; Chang HW; Wang TL; Shih IeM
Int J Gynecol Pathol; 2007 Apr; 26(2):141-6. PubMed ID: 17413980
[TBL] [Abstract][Full Text] [Related]
42. CD44 expression in benign, premalignant, and malignant ovarian neoplasms: relation to tumour development and progression.
Saegusa M; Machida D; Hashimura M; Okayasu I
J Pathol; 1999 Nov; 189(3):326-37. PubMed ID: 10547593
[TBL] [Abstract][Full Text] [Related]
43. Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH.
Joosse SA; van Beers EH; Tielen IH; Horlings H; Peterse JL; Hoogerbrugge N; Ligtenberg MJ; Wessels LF; Axwijk P; Verhoef S; Hogervorst FB; Nederlof PM
Breast Cancer Res Treat; 2009 Aug; 116(3):479-89. PubMed ID: 18704682
[TBL] [Abstract][Full Text] [Related]
44. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.
Motamed-Khorasani A; Jurisica I; Letarte M; Shaw PA; Parkes RK; Zhang X; Evangelou A; Rosen B; Murphy KJ; Brown TJ
Oncogene; 2007 Jan; 26(2):198-214. PubMed ID: 16832351
[TBL] [Abstract][Full Text] [Related]
45. Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas.
Dodson MK; Hartmann LC; Cliby WA; DeLacey KA; Keeney GL; Ritland SR; Su JQ; Podratz KC; Jenkins RB
Cancer Res; 1993 Oct; 53(19):4456-60. PubMed ID: 8402612
[TBL] [Abstract][Full Text] [Related]
46. [Expression of the cdx2 gene in benign intestinal-type mucinous ovarian tumors].
Gaggero G; Sola S; Mora M; Fulcheri E
Pathologica; 2003 Aug; 95(4):185-91. PubMed ID: 14577202
[TBL] [Abstract][Full Text] [Related]
47. Promoter methylation of sFRP5 in patients with ovarian clear cell adenocarcinoma.
Ho CM; Lai HC; Huang SH; Chien TY; Lin MC; Chang SF
Eur J Clin Invest; 2010 Apr; 40(4):310-8. PubMed ID: 20486992
[TBL] [Abstract][Full Text] [Related]
48. Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations.
Gonzalez R; Silva JM; Dominguez G; Garcia JM; Martinez G; Vargas J; Provencio M; España P; Bonilla F
Br J Cancer; 1999 Oct; 81(3):503-9. PubMed ID: 10507777
[TBL] [Abstract][Full Text] [Related]
49. [Hypermethylation of fragile histidine triad gene and 3p14 allelic deletion in ovarian carcinomas].
Hong FZ; Wang B; Li HM; Liew CT
Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):257-61. PubMed ID: 16181544
[TBL] [Abstract][Full Text] [Related]
50. Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression.
van Beerendonk HM; Rozeman LB; Taminiau AH; Sciot R; Bovée JV; Cleton-Jansen AM; Hogendoorn PC
J Pathol; 2004 Mar; 202(3):359-66. PubMed ID: 14991902
[TBL] [Abstract][Full Text] [Related]
51. Early loss of heterozygosity on 17q in ovarian cancer. The Abe Ovarian Cancer Genetics Group.
Eccles DM; Russell SE; Haites NE; Atkinson R; Bell DW; Gruber L; Hickey I; Kelly K; Kitchener H; Leonard R
Oncogene; 1992 Oct; 7(10):2069-72. PubMed ID: 1408149
[TBL] [Abstract][Full Text] [Related]
52. Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer.
Cavalli LR; Singh B; Isaacs C; Dickson RB; Haddad BR
Cancer Genet Cytogenet; 2004 Feb; 149(1):38-43. PubMed ID: 15104281
[TBL] [Abstract][Full Text] [Related]
53. Reduced expression of intercellular adhesion molecule-1 in ovarian adenocarcinomas.
Arnold JM; Cummings M; Purdie D; Chenevix-Trench G
Br J Cancer; 2001 Nov; 85(9):1351-8. PubMed ID: 11720474
[TBL] [Abstract][Full Text] [Related]
54. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.
Mirza S; Sharma G; Prasad CP; Parshad R; Srivastava A; Gupta SD; Ralhan R
Life Sci; 2007 Jul; 81(4):280-7. PubMed ID: 17599361
[TBL] [Abstract][Full Text] [Related]
55. Promoter hypermethylation profile of ovarian epithelial neoplasms.
Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO
Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849
[TBL] [Abstract][Full Text] [Related]
56. Loss of heterozygosity on chromosomes 7p, 7q, 9p and 11q is an early event in ovarian tumorigenesis.
Watson RH; Neville PJ; Roy WJ; Hitchcock A; Campbell IG
Oncogene; 1998 Jul; 17(2):207-12. PubMed ID: 9674705
[TBL] [Abstract][Full Text] [Related]
57. Frequent loss of heterozygosity on chromosomes 7 and 9 in benign epithelial ovarian tumours.
Roy WJ; Watson RH; Hitchcock A; Campbell IG
Oncogene; 1997 Oct; 15(17):2031-5. PubMed ID: 9366520
[TBL] [Abstract][Full Text] [Related]
58. Microsatellite analysis of breast carcinoma and corresponding local recurrences.
Regitnig P; Moser R; Thalhammer M; Luschin-Ebengreuth G; Ploner F; Papadi H; Tsybrovskyy O; Lax SF
J Pathol; 2002 Oct; 198(2):190-7. PubMed ID: 12237878
[TBL] [Abstract][Full Text] [Related]
59. BRCA1 and p53 protein expression in cultured ovarian surface epithelial cells derived from women with and without a BRCA1 germline mutation.
Piek JM; Dorsman JC; Massuger LF; Ansink AC; Weegenaar J; Shvarts A; Kenemans P; Verheijen RH
Arch Gynecol Obstet; 2006 Oct; 274(6):327-31. PubMed ID: 16826413
[TBL] [Abstract][Full Text] [Related]
60. [Correlation of genetic instability of nm23H1 gene to clinicopathologic features of epithelial ovarian carcinoma].
Yang YQ; Li JC
Ai Zheng; 2006 Jun; 25(6):713-7. PubMed ID: 16764766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
